Imugene Limited (ILA) - Net Assets

Latest as of : €- EUR

Based on the latest financial reports, Imugene Limited (ILA) has net assets worth €- EUR as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-
% of Total Assets	0%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

Imugene Limited - Net Assets Trend (None–None)

This chart illustrates how Imugene Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Imugene Limited (None–None)

The table below shows the annual net assets of Imugene Limited from None to None.

Year	Net Assets	Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to Imugene Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

No equity composition insights available.

Imugene Limited Competitors by Market Cap

The table below lists competitors of Imugene Limited ranked by their market capitalization.

Company	Market Cap
Datron AG XETRA:DAR	$30.88 Million
Auctus Alternative Investments Ltd AU:AVC	$30.88 Million
Victory New Materials Ltd Co TW:1340	$30.88 Million
Antilles Gold Ltd AU:AAU	$30.89 Million
Global Vectra Helicorp Limited NSE:GLOBALVECT	$30.88 Million
Chun Zu Machinery Industry Co., Ltd. TWO:4544	$30.87 Million
ALVIR PA:ALVIR	$30.87 Million
Qinetiq Group PLC LSE:QQ	$30.86 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Imugene Limited's equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares Imugene Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently Imugene Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares Imugene Limited's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $316,397,405
Average return on equity (ROE) among peers: -814.99%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Imugene Limited (ILA)	€-	N/A	N/A	$30.88 Million
09R (09R)	$-3.01 Million	0.00%	0.00x	$24.67 Million
PreveCeutical Medical Inc (18H)	$-6.64 Million	0.00%	0.00x	$3.34 Million
IDORSIA AG (19T)	$-968.72 Million	0.00%	0.00x	$978.02 Million
ONCOARENDI THERAP ZY-01 (1B1)	$100.93 Million	-28.11%	0.11x	$24.94 Million
Flerie AB (publ) (1NP1)	$4.20 Billion	-5.43%	0.01x	$231.62 Million
NUFORMIX PLC LS -001 (1RT)	$5.69 Million	-22.04%	0.06x	$1.53 Million
1S90 (1S90)	$13.78 Million	0.99%	9.14x	$70.17 Million
Strategic Partners A/S (1TB0)	$9.34 Million	-6708.84%	17.55x	$3.69 Million
Entheon Biomedical Corp. (1XU)	$614.57K	-1386.45%	0.25x	$502.28K
25K0 (25K0)	$-186.02 Million	0.00%	0.00x	$125.12 Million

About Imugene Limited

F:ILA Germany Biotechnology

Market Cap

$30.88 Million

€26.41 Million EUR

Market Cap Rank

#26352 Global

#3731 in Germany

Share Price

€0.08

Change (1 day)

-11.35%

52-Week Range

€0.07 - €0.20

All Time High

€0.20